Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 3 1Phase 2/3 1Phase 1/2 1

Status

Recruiting 4Active not recruiting 1

Sponsor Class

INDUSTRY 3OTHER 1NIH 1

Study Type

Interventional 5Observational 4

Sponsor

Cancer Type

Lymphoid 1

Conditions

Breast Neoplasms 311Carcinoma, Non-Small-Cell Lung 276Neoplasms 255Prostatic Neoplasms 216Colorectal Neoplasms 196Lung Neoplasms 153Multiple Myeloma 148Neoplasm Metastasis 135Ovarian Neoplasms 126Leukemia, Myeloid, Acute 123Pancreatic Neoplasms 116Melanoma 102Squamous Cell Carcinoma of Head and Neck 97Recurrence 85Endometrial Neoplasms 82Carcinoma, Renal Cell 80Glioblastoma 78Lymphoma, Non-Hodgkin 77Stomach Neoplasms 73Precursor Cell Lymphoblastic Leukemia-Lymphoma 72Lymphoma 72Carcinoma, Hepatocellular 72Glioma 65Brain Neoplasms 65Uterine Cervical Neoplasms 63Sarcoma 63Head and Neck Neoplasms 63Triple Negative Breast Neoplasms 59Leukemia, Lymphocytic, Chronic, B-Cell 58Urinary Bladder Neoplasms 55

Interventions

remdesivir 1fludarabine 1Specimen Handling 1Cyclophosphamide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Interventional × Autoimmune Diseases × 30 days × Clear all
NCT03922724 2026-06-05

Allogeneic Hematopoietic Cell Transplantation for Peripheral T Cell Lymphoma

National Institutes of Health Clinical Center (CC)

Phase 2 Recruiting
330 enrolled
Lymphoid

Autoimmune Diseases, Immune System Diseases, Lymphoproliferative Disorders, Opportunistic Infections, Lymphoma, T-Cell, Peripheral

NCT06817889 2026-06-03

Remdesivir for the Treatment of Upper Respiratory Tract Infection Due to RSV in Immunocompromised Individuals

Fred Hutchinson Cancer Center

Phase 2 Recruiting
60 enrolled

Autoimmune Diseases, Respiratory Syncytial Virus Infections

NCT07039916 2026-05-22

Study to Assess the Efficacy and Safety of IMVT-1402 in Participants With Mild to Severe Generalized Myasthenia Gravis

Immunovant Sciences GmbH

Phase 3 Recruiting
231 enrolled

Autoimmune Diseases, Myasthenia Gravis

NCT06359041 2026-05-18

RESET-MG: A Study to Evaluate the Safety and Efficacy of CABA-201 in Participants With Generalized Myasthenia Gravis

Cabaletta Bio

Phase 1/2 Active not recruiting
12 enrolled

Autoimmune Diseases, Myasthenia Gravis

NCT06193889 2026-05-15

KYSA-6: A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy, in Patients With Generalized Myasthenia Gravis

Kyverna Therapeutics

Phase 2/3 Recruiting
66 enrolled

Autoimmune Diseases, Myasthenia Gravis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡